Liraglutide Overdose-Induced Acute Pancreatitis

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2022 Mar 1

PMID 35228970

Authors

Aljawhara R AlSaadoun

Tariq R AlSaadoun

Abdullah K Al Ghumlas

Affiliations

Soon will be listed here.

Abstract

Liraglutide, a long-acting cardioprotective glucagon-like peptide (GLP)-1 analog, is effective for medical weight loss and glycemic control in type 2 diabetes. It is generally well tolerated with mild side effects. There are few reports on complications from Liraglutide overdose. The aim of this paper is to report the case of a 25-year-old healthy female who presented with acute pancreatitis secondary to Liraglutide overdose and to review the current literature on Liraglutide used for obesity management. The current literature examining the association between acute pancreatitis and Liraglutide use, and Liraglutide overdose are inconclusive. Further research is recommended.

Citing Articles

Association between different GLP-1 receptor agonists and acute pancreatitis: case series and real-world pharmacovigilance analysis.

Guo H, Guo Q, Li Z, Wang Z Front Pharmacol. 2024; 15:1461398.

PMID: 39605914 PMC: 11600108. DOI: 10.3389/fphar.2024.1461398.

The effect of incretin-based drugs on the riks of acute pancreatitis: a review.

Czaplicka A, Kaleta B J Diabetes Metab Disord. 2024; 23(1):487-495.

PMID: 38932809 PMC: 11196466. DOI: 10.1007/s40200-024-01430-6.

Oral Delivery of Liraglutide-Loaded Zein/Eudragit-Chitosan Nanoparticles Provides Pharmacokinetic and Glycemic Outcomes Comparable to Its Subcutaneous Injection in Rats.

Ziebarth J, da Silva L, Lorenzett A, Figueiredo I, Carlstrom P, Cardoso F Pharmaceutics. 2024; 16(5).

PMID: 38794296 PMC: 11125159. DOI: 10.3390/pharmaceutics16050634.

Liraglutide-Induced Pancreatitis: A Case Report and Literature Review.

Javed H, Jagirdhar G, Kashyap R, Vekaria P Cureus. 2023; 15(4):e38263.

PMID: 37252522 PMC: 10225244. DOI: 10.7759/cureus.38263.

Analysis of acute pancreatitis associated with SGLT-2 inhibitors and predictive factors of the death risk: Based on food and drug administration adverse event report system database.

Zhang L, Mao W, Li X, Wang X, Liu J, Hu S Front Pharmacol. 2022; 13:977582.

PMID: 36467046 PMC: 9716078. DOI: 10.3389/fphar.2022.977582.

References

Nyborg N, Molck A, Madsen L, Knudsen L . The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species. Diabetes. 2012; 61(5):1243-9. PMC: 3331765. DOI: 10.2337/db11-0936. View

Nauck M, Quast D, Wefers J, Meier J . GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2020; 46:101102. PMC: 8085572. DOI: 10.1016/j.molmet.2020.101102. View

Patel D, Stanford F . Safety and tolerability of new-generation anti-obesity medications: a narrative review. Postgrad Med. 2018; 130(2):173-182. PMC: 6261426. DOI: 10.1080/00325481.2018.1435129. View

Chalmer T, Almdal T, Vilsboll T, Knop F . Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes--focus on pancreatitis and pancreas cancer. Expert Opin Drug Saf. 2014; 14(1):171-80. DOI: 10.1517/14740338.2015.975205. View

Nafisah S, Almatrafi D, Al-Mulhim K . Liraglutide overdose: A case report and an updated review. Turk J Emerg Med. 2020; 20(1):46-49. PMC: 7189825. DOI: 10.4103/2452-2473.276386. View

Alves C, Batel-Marques F, Macedo A . A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Diabetes Res Clin Pract. 2012; 98(2):271-84. DOI: 10.1016/j.diabres.2012.09.008. View

Inzucchi S, Bergenstal R, Buse J, Diamant M, Ferrannini E, Nauck M . Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012; 35(6):1364-79. PMC: 3357214. DOI: 10.2337/dc12-0413. View

Solverson K, Lee H, Doig C . Intentional overdose of liraglutide in a non-diabetic patient causing severe hypoglycemia. CJEM. 2018; 20(S2):S61-S63. DOI: 10.1017/cem.2017.439. View

Krentz A, Fujioka K, Hompesch M . Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles. Diabetes Obes Metab. 2016; 18(6):558-70. DOI: 10.1111/dom.12657. View

10.

Bowler M, Nethercott D . Two lessons from the empiric management of a combined overdose of liraglutide and amitriptyline. A A Case Rep. 2015; 2(3):28-30. DOI: 10.1097/ACC.0b013e3182a526fa. View

11.

Bode S, Egg M, Wallesch C, Hermanns-Clausen M . 10-fold liraglutide overdose over 7 months resulted only in minor side-effects. J Clin Pharmacol. 2013; 53(7):785-6. DOI: 10.1002/jcph.94. View

12.

Knudsen L, Lau J . The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol (Lausanne). 2019; 10:155. PMC: 6474072. DOI: 10.3389/fendo.2019.00155. View

13.

Drucker D, Sherman S, Bergenstal R, Buse J . The safety of incretin-based therapies--review of the scientific evidence. J Clin Endocrinol Metab. 2011; 96(7):2027-31. DOI: 10.1210/jc.2011-0599. View

14.

Madsbad S . Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab. 2015; 18(4):317-32. PMC: 5064617. DOI: 10.1111/dom.12596. View

15.

Nakanishi R, Hirose T, Tamura Y, Fujitani Y, Watada H . Attempted suicide with liraglutide overdose did not induce hypoglycemia. Diabetes Res Clin Pract. 2012; 99(1):e3-4. DOI: 10.1016/j.diabres.2012.10.017. View

16.

Verspohl E . Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther. 2009; 124(1):113-38. DOI: 10.1016/j.pharmthera.2009.06.002. View